Four Anchorage men have been diagnosed with mpox despite reporting no travel outside Alaska, raising the prospect of local transmission and marking the state’s first confirmed infections involving the clade Ib strain, Juneau Empire reported.
The Alaska Department of Health confirmed three cases on Oct. 29, all male patients, with an epidemiologic link identified only between the first two. A fourth case was reported to state officials on Nov. 5, bringing the annual total to four — the most since five cases were recorded during the 2022 outbreak.
Only two infections were reported statewide between 2023 and 2025. One patient was briefly hospitalized; all are isolating and recovering, according to an Alaska Public Health Alert Network notice.
“It’s too early to draw that conclusion,” Peter Costa, North American medical affairs director for Bavarian Nordic, told Juneau Empire when asked if the virus could begin circulating regularly in Alaska.
The strain difference
An August CDC report found that clade IIb was still spreading at low levels in 2024 and 2025.
Vaccination gaps persist
Alaska’s recent cases have drawn attention to gaps in vaccination coverage. The mpox vaccine, Jynneos, is given in two doses, typically four weeks apart.
That leaves roughly 250 Alaskans who started but never completed the series.
Costa said people who received their first dose years ago do not need to restart the series. Jynneos became commercially available in 2024 and was added to the adult immunization schedule that year.
Transmission and clinical picture
The incubation period is typically three to 17 days. Prodromal symptoms include fever, chills, fatigue, headache, myalgias and lymphadenopathy, though some patients present with rash only. The rash progresses from macules to papules, vesicles, pustules and scabs. Lesions are often firm, well-circumscribed, umbilicated and tender, frequently occurring on the genitals, anorectal area, mouth, palms, soles or elsewhere.
Who should consider the vaccine
Travelers to countries with clade I transmission who anticipate sexual activities associated with increased exposure risk are also included in the CDC’s guidance.
Costa said some healthcare providers may not know that Jynneos became commercially available in 2024. He urged clinicians to discuss mpox with patients during sexual health appointments, particularly those involving sexually transmitted infections or HIV prevention medication.
Post-exposure options
Vaccination can provide protection after exposure, too.
Mpox vaccinations are available through the Juneau Public Health Center at 3412 Glacier Highway. Residents can call 907-465-3353 for eligibility, availability and appointments.
With the origin of Anchorage’s infections still under investigation, Costa said improving those clinical discussions could help prevent another outbreak similar to the one in 2022.